Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.

Breast Cancer Res Treat · 2013 · PMC3825616 · PMID 24122389

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, patients with mid-range Ki67LI (10–20 %) showed a trend towards improved pCR rate with docetaxel/capecitabine compared to docetaxel alone.

also in 53,322 other papers

an interesting trendno p-value reported

However, we observed an interesting trend in the subset of patients who had discontinued treatment or received a 25 % dose reduction.

also in 1,783 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.